Update on INSTIs (AME)

This edition provides an update on HIV integrase strand transfer inhibitors (INSTI), compiling for you data from relevant clinical trials that have assessed the efficacy, toxicity, and resistance.

The latest trends in treatment strategies are critically reviewed, such as moving to simpler antiretroviral regimens to reduce the drug burden for people living with HIV.
Although modern antiretroviral therapy (ART) and INSTIs are generally safer and better tolerated, reported adverse events will be discussed and important principles when interpreting those will be covered.
Finally, a special focus will be given on the use of INSTIs in middle-income countries, where HIV presents a heavy burden. INSTI-based regimes are the preferred first-line options and information will be provided on the current treatment guidelines. The remaining issues will be raised with regard to structural barriers that need to be lifted in order to achieve the 90-90-90 targets.
Follow this edition of the Online Meeting Highlights to learn more on the clinical utility of integrase inhibitors as a treatment option for your HIV patients.
After following this eLearning activity, you will be able to:

• Evaluate optimal use of integrase inhibitors available in middle income countries;
• Comprehend toxicity associated to integrase inhibitors-based regimens; and
• Evaluate optimal use of reduced drug regimens.

To obtain your certificate, you have complete all three modules, passed the relevant assessments and answered the evaluation survey.
Module 1 | Optimal Use of INSTI in Middle Income Countries
Module 2 | Update on INSTI Toxicity
Module 3 | Reduced Drug Regimens
Duration: approximately 20 minutes per module
You can enhance your learning experience by:

• adding notes to the video modules;
• consulting the accompanying presentation slides;
• sharing your questions and observations with other learners in the discussion board; and
• referring to further literature and other materials provided to you by our experts.

The program is aimed at clinicians from various specialties who occasionally treat HIV patients, such as primary care physicians, family doctors, OBGYN, transgender healthcare clinicians, adolescent medicine professionals, and preventive medicine professionals, as well as public health workers and researchers engaged in HIV related disciplines at varying degrees.